Chemotherapy of cervix cancer with mitolactol (dibromodulcitol, NSC 104800) and cisplatin: A Phase I study of the Gynecologic Oncology Group

G. A. Omura, J. L. Hubbard, K. D. Hatch, J. B. Schlaerth, J. A. Blessing

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

In this Phase I study, thirteen women with advanced cervix cancer were treated with mitolactol (dibromodulcitol) plus cisplatin to determine a maximum tolerable dose schedule. Response was not an objective of this study, but four partial responses were seen in nine patients with measurable lesions. In general, the therapy was well tolerated, but of the ten patients treated at the first dose level (cisplatin 50 mg/m2 intravenously on day 1 plus mitolactol 180 mg/m2 orally on days 2-6 every 3-4 weeks), 5 required deescalations and 8 required delays because of toxicity. All three patients treated with cisplatin plus a higher dose of mitolactol (270 mg/m2 x 5) required dose reductions and delays for hematologic toxicity. The first dose level appears tolerable by patients with, and promising in treating, advanced cervix cancer.

Original languageEnglish (US)
Pages (from-to)185-187
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume15
Issue number3
DOIs
StatePublished - 1992

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Chemotherapy of cervix cancer with mitolactol (dibromodulcitol, NSC 104800) and cisplatin: A Phase I study of the Gynecologic Oncology Group'. Together they form a unique fingerprint.

  • Cite this